Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients

NCT05525741 | Active Not Recruiting

• 1 other identifier: 22-PP-10
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 1

Brief Summary

To compare the level of circulating functional mitochondria in the serum of vitiligo patients as compared to controls

Conditions

Skin and Connective Tissue Diseases

Outcome Measures

Primary Outcomes (1)

• Total number of circulating functionnal mitochondria (CFM) in the plasma

  Level of CFM in vitiligo serum as compared to controls

  at baseline

Secondary Outcomes (1)

• measuring the functionality of circulating mitochondria

  At baseline

Study Arms (2)

Vitiligo Group

EXPERIMENTAL

If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Other: Non segmental vitiligo

Volunteers Group

OTHER

If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Other: Health Volunteers

Interventions

Non segmental vitiligo OTHER

The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: * Inform the subject of the goals, constraints and risks of the study and obtain written consent. * Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Vitiligo Group

Health Volunteers OTHER

The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: * Inform the subject of the goals, constraints and risks of the study and obtain written consent. * Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Volunteers Group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with non segmental vitiligo,
• atopic dermatitis, psoriais, alopecia areata,
• st degree relative of vitiligo patients.

You may not qualify if:

• segmental or mixed vitiligo,
• personnal history of other autoimmune disorders,
• oral use of antioxidant,
• pregant women

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (1)

CHU de Nice - Hôpital de l'Archet

Nice, Alpes-maritimes, 06200, France

Location

MeSH Terms

Conditions

Skin and Connective Tissue Diseases

Study Officials

• passeron thierry, PhD

  CHU de Nice, Service de Dermatologie

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Patients with non segmental vitiligo compared to healthy volunteers (1st degree family of vitiligo patients) atopic dermatitis, psoriasis and alopecia areata patients

Study Record Dates

• First Submitted: August 23, 2022
• First Posted: September 2, 2022
• Study Start: October 19, 2022
• Primary Completion: April 1, 2023
• Study Completion: June 30, 2025
• Last Updated: December 4, 2024

Record last verified: 2024-12

Locations

FR (1)